Article Sidebar

pdf
Date Published: 15/04/2024
Abstract Views: 122
Views pdf: 75
DOI: https://doi.org/10.51298/vmj.v537i2.9260
Issue
Vol. 537 No. 2 (2024)
Section
Các bài báo
How to Cite
Vi, T. A., Lê, T. Đức, & Lê, C. Đại. (2024). RESULTS OF DOCETAXEL STEP 2 CHEMOTHERAPY FOR LATE STAGE NON-SMALL CELL LUNG CANCER AT NGHE AN ONCANCE HOSPITAL. Vietnam Medical Journal, 537(2). https://doi.org/10.51298/vmj.v537i2.9260

RESULTS OF DOCETAXEL STEP 2 CHEMOTHERAPY FOR LATE STAGE NON-SMALL CELL LUNG CANCER AT NGHE AN ONCANCE HOSPITAL

Tuấn Anh Vi, Thanh Đức Lê, Chính Đại Lê

Main Article Content

Abstract

Objective: Evaluate the results of Docetaxel step 2 regimen in the treatment of non-small cell lung cancer. Methods: Clinical descriptive design, longitudinal follow-up on 59 patients treated at Internal Medicine Department 2, Nghe An Oncology Hospital from June 2021 to June 2023. Evaluation criteria were improvement in clinical symptoms (mechanical response) and RECIST criteria (physical response). Results: Cough symptoms decreased from 72.9% to 40.1%; Chest pain decreased from 83% to 55.9%; Shortness of breath and bone pain improved slowly. The rate of disease progression is 54%; The lowest is partial response, accounting for 15%; 31% of patients are stable. The average progression-free survival time was 7.6±3.0 (months), the average overall survival time was 13.6±6.9 months. Conclusion: Docetaxel is effective in the second-line treatment of non-small cell lung cancer.

Article Details

Keywords

non-small cell lung cancer, second step chemotherapy.

References

1. Nguyễn Việt Hà, Đặng Văn Khoa (2013), Đánh giá hiệu quả phác đồ Paclitaxel – Cisplatin trong điều trị ung thư phổi không tế bào nhỏ giai đoạn IIIB- IV, Tạp chí Y học thực hành, (873) – số 6/2013, 28- 31.
2. Bùi Xuân Thắng, Nguyễn Thị Thu Hường (2023). Kết quả điều trị duy trì Docetaxel sau hoá chất phác đồ Paclitaxel – Cisplatin trong ung thư phổi không tế bào nhỏ giai đoạn IV tại bệnh viện K, Tạp chí Y học Việt Nam, 522(1), tr 265-269.
3. Shepherd F.A., Dancey J, Arnold et al (2001) Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma. Cancer, 92, 595-600.
4. McGuire, Shelley. World cancer report 2014. Geneva, Switzerland: World Health Organization, international agency for research on cancer, WHO Press, 2015. Advances in nutrition 7.2 (2016): 418-419.
5. Belani CP, Yamamoto N, Bondarenko IM et al (2014). Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. BMC Cancer, 14, 290.
6. WHO (2015). Pathology and genetics of tumours of the lung, pleure, thymus and hearts. 4 ed: Lyon: IARC Press.
7. Kawano Y, Ohyanagi F, Yanagitani N et al (2013). Pemetrexed and cisplatin for advanced non-squamous non-small cell lung cancer in Japanese patients: phase II study. Anticancer Res, 33(8), 3327-33.